A double-blind, placebo-controlled, randomized trial was conducted on patients suffering from a stroke and demonstrated that high doses of erythropoietin (Epo) (33 000 IU/day during 3 days) was well tolerated and safe [63]. The gene discussed is EPO; the disease is stroke disorder.